In a prospectively performed cytometry of tumors from patients with NSCLC, we identified five tumors harboring mutations in TSC1 or TSC2, and these tumors also had significantly increased CD8+/CD3+ ratio and higher PD-1 MFI of CD8+ T cells than TSC1/TSC2-WT tumors (n = 15, P < 0.01; Fig. 4H). This evidence concerns the gene TSC1 and non-small cell lung carcinoma.